Similarly,
Weight gain obesity medication:
Medicines promoting weight loss are currently very promising. However, according to a study, after the judgment of certain active ingredients, the effect is reversed rapidly.
People who have received the active ingredients have lost weight significantly during treatment. Furthermore, a loss that has even continued, to a lesser extent, for a few weeks after stopping treatment, according to the team led by Han Wu and Wenjia Yang from the Popular Hospital of the University of Beijing.
However. Meanwhile, from the eighth week following the end of the treatment, the researchers noticed a significant weight gain which continued for several weeks.
According to the study. Consequently, the extent of weight gain varies depending on the medication and lifestyle changes, but there is a clear tendency to gain weight after stopping the medication.
A weight gain obesity medication Luxembourg doctor identified for the abusive prescription of Ozempic
Significant increase after stopping treatment
According to Stephan Martin. In addition, a diabetology chief doctor and director of the West German Center for Diabetes and Health of the Düsseldorf Catholic Clinics, this confirms the existing conclusions.
Some drug manufacturers have also demonstrated this phenomenon through randomized trials, reports an expert not involved in evaluated studies. For example, the subjects received the active ingredients for ten weeks, then a placebo. For example, This group “then gradually regained weight,” reports Stephan Martin.
In the current study. Beijing researchers also refer to a study that people who had finished 36 weeks of treatment with the drug tirzepatide (GLP-1-RA) resumed about half of the weight they had lost before a year after having passed to a placebo.
Tips to avoid blood sugar peaks. weight gain obesity medication lose weight more easily
The effects of several groups of drugs studied
For the now published meta-analysis, the results of eleven independent studies carried out around the world have been synthesized, in particular on the Orlistat, the Naltrexone/Bupropion and Phentermate/Topiramate associations, as well as on GLP-1’s agonists. The data comes from 1,574 people in processing groups and 893 in control groups.
GLP-1 (AR GLP-1) receptors agonists, for example, are present in popular drugs Wegovy and Ozempic. They are approved in Germany for the treatment of type 2 diabetes. certain cases of obesity, and are known as food supplements for a slender silhouette.
Faced with the global obesity epidemic. a study pleads for urgent action
The active ingredients, regularly injected, mainly extend the stay of food in the digestive tract, thus increasing the feeling of satiety. Side effects include weight gain obesity medication gastrointestinal disorders.
One aspect of the study stands out: according to data. people who initially experienced significant weight loss during therapy then resumed weight, even if patients then participated in a program aimed at modifying their lifestyle, such as their eating and exercise habits.
“It doesn’t surprise me,” said Anja Hilbert, a behavioral medical professor at Leipzig University Hospital. People following a severe hypocaloric diet. for example, obtain a similar result: they also resume more weight after the diet than, for example, those according to a moderate calorie restriction. The expert specifies, however, that the participants in this aspect of the study were few.
Why is overweight so dangerous?
“You need this therapy permanently”
“The results of the study suggest that long -term use. even for life, may be necessary to stabilize the weight,” concludes Anja Hilbert. weight gain obesity medication Stephan Martin also underlines: “It is long -term therapy.” Those who think they can lose weight with this therapy and that everything will be very mistaken. “You need this therapy permanently.”
However, figures from the United States arouse concerns: many people ignore this phenomenon or simply accept it, explains Martin. Studies in the United States show that two thirds of persons treated for obesity. most of them have stopped treatment after a year. “We do not know why: maybe it becomes too expensive. maybe they have lost weight enough and think it will last,” explains the chief doctor of the diabetology department, who advocates prevention than the treatment of consequences.
The cost is also a problem in Germany: “GLP-1-RA treatment costs several hundred euros per month. and around 23% of our population is obese,” explains Anja Hilbert, who also promotes obesity prevention. “If we calculate the weight gain obesity medication cost of permanent access to these drugs for all those concerned. we understand how difficult their funding would be.”
This article was initially published On the Luxemburger Wort website.
It was translated using artificial intelligence tools that learn from data from human translations, then checked by Cécile Vicini.
Further reading: The US Senate approves $ 9 billion in budget cuts requested by Trump – At menopause, sleep is essential for heart health – New Kaftrio and Kalydeco specialties adapted to the child from 2 to 6 years old – This activity is the best to protect cognitive functions and the brain – target the prevention of hepatitis B and obesity to stop an explosion of cases.